ArticleThorax1997
Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis.
Article in Thorax, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 50 citations in OpenAlex.
- Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.Clinical and vaccine immunology : CVI · 2011Trial
- The interplay between M2-like macrophages and Th17.1 cells promotes the progression of early-stage sarcoidosis.Cell communication and signaling : CCS · 2025Article
- Follicular Helper-like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis.American journal of respiratory and critical care medicine · 2021Article
- Article
- RNA-sequencing Identifies Novel Pathways in Sarcoidosis Monocytes.Scientific reports · 2017Article
- Low-dose Naltrexone for the treatment of sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2017Article
- Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients.Respiratory research · 2016Article
- Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis.Fibrogenesis & tissue repair · 2011Article
- The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques.Inflammopharmacology · 2011Review
- Pulmonary fibrosis: pathogenesis, etiology and regulation.Mucosal immunology · 2009Review
- Expression profiling in granulomatous lung disease.Proceedings of the American Thoracic Society · 2007Review
- Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells.Respiratory research · 2005Article
- Possible role of L-selectin in T lymphocyte alveolitis in patients with active pulmonary sarcoidosis.Clinical and experimental immunology · 2000Article
- Immunophenotyping of bronchoalveolar lavage lymphocytes.Clinical and diagnostic laboratory immunology · 1998Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a systemic granulomatous disorder of unknown origin characterised by accumulation of T lymphocytes and macrophages in multiple organs. Several cytokines and adhesion molecules may contribute to the accumulation of T lymphocytes in pulmonary sarcoidosis. The distribution of T lymphocyte subsets, T cell bearing CD11a and beta chemokines such as regulated on activation normal T expressed and secreted (RANTES), macrophage inflammatory peptide 1 alpha (MIP-1 alpha), and macrophage chemoattractant protein 1 (MCP-1) in bronchoalveolar lavage (BAL) fluid and peripheral blood were compared in untreated patients with sarcoidosis and normal subjects.
methodsFlow cytometric analysis with monoclonal antibodies to cell surface antigens was used to identify T lymphocyte subsets in the BAL fluid of untreated patients with sarcoidosis (n = 40)--either without (group A, n = 12) or with (group B, n = 28) radiological evidence of pulmonary involvement--and in 22 normal subjects. The level of different beta chemokines was estimated by enzyme linked immunosorbent assay (ELISA).
resultsA high percentage of CD3+ cells, CD4+ cells expressing HLA-DR antigen, and a high CD4/CD8 ratio were detected in the BAL fluid of patients compared with normal subjects. In particular, CD4+ CD29+ memory T cells were significantly increased in patients with sarcoidosis. Furthermore, these cells were higher in those in group B than group A. The level of RANTES in the BAL fluid of patients was significantly higher than in normal subjects and correlated well with the percentage, number, and expression of CD29 on CD4 cells. The expression of CD11a (alpha chain of lymphocyte function associated antigen-1, LFA-1) on CD3+ cells in the BAL fluid of patients with sarcoidosis was not different from that of normal subjects. However, the expression of CD11a on CD3+ cells in the BAL fluid of patients in group A was significantly lower than that of patients in group B and normal subjects.
conclusionsThese results suggest a possible interaction between activated memory T cells bearing CD11a and RANTES which may contribute to the pulmonary involvement in patients with sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.